Adolescents with clinical type 1 diabetes display reduced red blood cell glucose transporter isoform 1 (GLUT1)

Pediatr Diabetes. 2014 Nov;15(7):511-8. doi: 10.1111/pedi.12127. Epub 2014 Feb 19.

Abstract

Type 1 diabetic (T1D) adolescent children on insulin therapy suffer episodes of both hyper- and hypoglycemic episodes. Glucose transporter isoform GLUT1 expressed in blood-brain barrier (BBB) and red blood cells (RBC) compensates for perturbed circulating glucose toward protecting the supply to brain and RBCs. We hypothesized that RBC-GLUT1 concentration, as a surrogate for BBB-GLUT1, is altered in T1D children. To test this hypothesis, we measured RBC-GLUT1 by enzyme-linked immunosorbent assay (ELISA) in T1D children (n = 72; mean age 15.3 ± 0.2 yr) and control children (CON; n = 11; mean age 15.6 ± 0.9 yr) after 12 h of euglycemia and during a hyperinsulinemic-hypoglycemic clamp with a nadir blood glucose of ~3.3 mmol/L for 90 min (clamp I) or ~3 mmol/L for 45 min (clamp II). Reduced baseline RBC-GLUT1 was observed in T1D (2.4 ± 0.17 ng/ng membrane protein); vs. CON (4.2 ± 0.61 ng/ng protein) (p < 0.0001). Additionally, baseline RBC-GLUT1 in T1D negatively correlated with hemoglobin A1c (HbA1c) (R = -0.23, p < 0.05) but not in CON (R = 0.06, p < 0.9). Acute decline in serum glucose to 3.3 mmol/L (90 min) or 3 mmol/L (45 min) did not change baseline RBC-GLUT1 in T1D or CON children. We conclude that reduced RBC-GLUT1 encountered in T1D, with no ability to compensate by increasing during acute hypoglycemia over the durations examined, may demonstrate a vulnerability of impaired RBC glucose transport (serving as a surrogate for BBB), especially in those with the worst control. We speculate that this may contribute to the perturbed cognition seen in T1D adolescents.

Keywords: BBB; RBC glucose transporter 1; T1D; hyperinsulinemic clamp; hypoglycemic clamp.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Biomarkers / blood
  • Blood Glucose / analysis
  • Blood-Brain Barrier / drug effects
  • Blood-Brain Barrier / metabolism*
  • Cognition Disorders / complications
  • Diabetes Mellitus, Type 1 / blood
  • Diabetes Mellitus, Type 1 / complications
  • Diabetes Mellitus, Type 1 / drug therapy
  • Diabetes Mellitus, Type 1 / metabolism*
  • Down-Regulation* / drug effects
  • Enzyme-Linked Immunosorbent Assay
  • Erythrocytes / drug effects
  • Erythrocytes / metabolism*
  • Glucose Clamp Technique
  • Glucose Transporter Type 1 / blood*
  • Glycated Hemoglobin / analysis
  • Humans
  • Hyperglycemia / prevention & control
  • Hypoglycemia / chemically induced
  • Hypoglycemia / prevention & control
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use
  • Insulin / pharmacology
  • Insulin / therapeutic use
  • Models, Biological*
  • Prospective Studies

Substances

  • Biomarkers
  • Blood Glucose
  • Glucose Transporter Type 1
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Insulin
  • SLC2A1 protein, human
  • hemoglobin A1c protein, human